Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Biol Psychiatry. 2015 Oct 30;79(7):516–525. doi: 10.1016/j.biopsych.2015.07.028

Fig. 2. Potential synthetic and degradative pathways for anandamide and 2-AG.

Fig. 2

A. Primary synthetic pathways for anandamide. B. Primary degradative pathways for anandamide. C. Primary synthetic pathways for 2-AG. D. Primary degradative pathways for 2-AG. Only major pathways are shown. More comprehensive details can be found in recent reviews (131–133). Abbreviations: AA, arachidonic acid; ABHD4, alpha/beta domain-containing hydrolase 4; ABHD6, alpha/beta domain-containing hydrolase 6; ABHD12, alpha/beta domain-containing hydrolase 12; COX-2, cyclooxygenase-2; DAG, diacylglycerol; DAGL, diacylglycerol lipase; FAAH, fatty acid aminohydrolase; GDE-1, glycerophosphodiesterase GDE-1; IP3, inositol tris-phosphate; LPA, lyso-phosphatidic acid; lyso-PLC, lyso-phospholipid-preferring phospholipase C; MAGL, monoacyl glycerol lipase; NAAA, N-acyl ethanolamine amino hydrolase; NAPE-PLD, N-arachidonoyl phosphatidyl ethanol-preferring phospholipase D; PIP2, phosphatidyl inositol bis-phosphate; Pi, PO4; PLA2, phospholipase A2; PLC, phospholipase C;